title: Imaging technologies in drug development: Anxiety and depression.
abstract: Imaging technologies provide a unique access to the human brain in vivo. The use of imaging in anxiety and depression drug development has the potential to shorten and reduce the cost of the drug development process. Principles and assumptions inherent in diverse imaging technologies need be kept in mind to ensure data obtained are not misleading. A consideration of questions commonly encountered in drug development suggests specific imaging methodologies to be used to explore these.:
authors: Imaging Applications Group, Translational Medicine and Genetics, GlaxoSmithKline Pharmaceuticals, Addenbrooke's Centre for Clinical Investigation, Addenbrooke's Hospital, Box 128, Hills Road, Cambridge, UK CB2 2GG. Electronic address:Eugenii.A.Rabiner@gsk.com.
authors: Eugenii A
authors: EA
authors: Rabiner